- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01581450
Hyperalgesia and Pain
Evaluation of Antihyperalgesic and Analgesic Effects of 35% Nitrous Oxide in a Human Model of Electrically Evoked Hyperalgesia and Pain
Evaluation of the effects of 35%/15%/50% N2O/N2/O2 mixtures on the area of hyperalgesia induced by remifentanil in the CCES (Continuous Cutaneous Electrical Stimulation) model in 20 healthy volunteers.
The duration of participation for each volunteer is expected to be around 9 weeks with the performance of 4 experimental session 2 weeks apart.
The selection visit will last half a day; each experimental session will last half a day; the study end will last 2 hours maximum.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Single site, exploratory, comparative, double-blind, randomised, cross-over study. Three physicians will be involved in the conduct of this study:
- Physician 1 will include and randomise the subjects, prepare and administer the study products (namely Investigational Medicinal Products (IMPs)) in an open manner and will assess subject safety.
- Physician 2, kept IMP blinded, will perform all evaluation measurements and sedation assessments during all experimental sessions. Physician 2 will always be the same person throughout the whole study period.
- Physician 3 will be available if needed to reinforce subject safety
Design: A group of 20 assessable subjects who will undergo 4 randomised experimental sessions of CCES on 4 separate study days, 2 weeks apart preceded by a 2 week period between selection and first experimental session and followed by a 1 week period between last experimental session and study end.
After the selection visit, each visit corresponds to one of the 4 experimental sessions named A, B, C, D differing by the gas mixture inhaled and the intravenous medicine administered.
The order of these experimental sessions A, B, C, D, will be assigned according to a pre-established list that the investigator will not know.
Each experimental session includes a set-up-phase followed by an evaluation phase.
The set up phase will last 20 mn during each an electrical stimulation will generate a spontaneous pain: every 2 minutes the electrical stimulation will increase and the subject will be asked to rate the pain on a visual scale from 0 to 100. When a stable levels of pain intensity will be reached, the regimen of the electrical stimulation will be kept constant up to the end of the experimental session.
The Evaluation phase will last 160 mn : the electrical stimulation will be constant during 160 mn as detailed above. During this phase the subject will inhale a gas mixture with a face mask during 60 minutes combined with an intravenous administration of medicine during 30 mn starting at the same time.
Every 5 minutes the subject will be asked to rate the pain and at predefined times the spontaneous pain and the area of allodynia and hyperalgesia will be measured and recorded as well as safety parameters (transcutaneous oxygen saturation, respiratory parameters, sedation score, blood pressure and heart rate).
The 4 experimental sessions named A, B, C, D differ by the gas mixture inhaled and the intravenous medicine administered.
For the placebo session, inhaled gas mixture will be 50%/50% N2/O2 and intravenous administration will be an isotonic saline solution.
For the three other sessions, inhaled gas mixture will differ from a session to the other one (35%/15%/50% N2O/N2/O2 or 50%/50% N2/O2 or 50%/50% N2O/O2), and remifentanil will be administered intravenously at each of these sessions.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Erlangen, Germany, 91054
- University of Erlangen - Nürnberg
-
Erlangen, Germany
- University of Erlangen - Nürnberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Caucasian healthy male
- Able to feel a distinct pin-pick sensation on normal skin
- Subject willing and able to complete the requirements of this study
- Written informed consent signed prior to any study related procedures
Exclusion Criteria:
- History of any past or current renal, hepatic, cardiovascular, pulmonary, gastrointestinal, metabolic, endocrine haematological, neurological, psychiatric disease or other disorders
- Any significant history of allergic disease
- Acute skin disease, lesions, acute sunburn, extensive tattoos or scars
- Donation of blood within the previous 3 months
- participation in any other clinical study within the previous 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Tested drug
Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
|
35%
50%
Other Names:
|
ACTIVE_COMPARATOR: Gas Active control
Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
|
35%
50%
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hyperalgesia
Time Frame: at T0, T10, T25, T40, T55, T70, T95, T110, T125, T140 and T155 minutes at each experimental session which will last half day
|
- Hyperalgesia will be assessed by using a metal rod,(in unit cm).
|
at T0, T10, T25, T40, T55, T70, T95, T110, T125, T140 and T155 minutes at each experimental session which will last half day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
transcutaneous oxygen saturation
Time Frame: From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
By monitoring pulse oximetry device
|
From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
respiration rate
Time Frame: From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
Respiration rate
|
From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
systolic and diastolic blood pressures
Time Frame: From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
systolic and diastolic blood pressures
|
From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
Heart rate
Time Frame: From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
Measured by cardioscope
|
From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
sedation score
Time Frame: From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
sedation score
|
From T0 to T160 minutes, at 5 minute intervals at each experimental session which will last half day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andreas WEHRFRITZ, MD, University of Erlangen-Nürnberg - Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Sensation Disorders
- Somatosensory Disorders
- Hyperalgesia
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, General
- Anesthetics
- Analgesics, Non-Narcotic
- Anesthetics, Inhalation
- Nitrous Oxide
Other Study ID Numbers
- 2011-000966-37
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperalgesia
-
Second Affiliated Hospital, School of Medicine,...RecruitingPostoperative HyperalgesiaChina
-
Wonkwang University HospitalCompletedHyperalgesia, MechanicalKorea, Republic of
-
The Second Affiliated Hospital of Chongqing Medical...CompletedPostoperative HyperalgesiaChina
-
University of WashingtonCompletedHyperalgesia, SecondaryUnited States, Brazil
-
National Institute on Drug Abuse (NIDA)Unknown
-
Ullevaal University HospitalUniversity of Oslo; Rikshospitalet University HospitalCompleted
-
Cambridge University Hospitals NHS Foundation TrustWithdrawn
-
University Hospital, Basel, SwitzerlandCompletedPain Perception | Secondary HyperalgesiaSwitzerland
-
Rigshospitalet, DenmarkCompleted
-
University of California, Los AngelesCompletedOpioid-Induced HyperalgesiaUnited States
Clinical Trials on Nitrous Oxide
-
University of ChicagoNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Opioid-Related DisordersUnited States
-
State University of New York at BuffaloCompleted
-
Washington University School of MedicineBrain & Behavior Research FoundationCompletedDepressive Disorder, Major | Depressive Disorder, Treatment-ResistantUnited States
-
Beth Israel Deaconess Medical CenterBoston Children's HospitalCompletedLower Urinary Tract SymptomsUnited States
-
Beth Israel Deaconess Medical CenterRecruitingProcedural Pain | Pain Catastrophizing | Procedural AnxietyUnited States
-
Beth Israel Deaconess Medical CenterBrigham and Women's HospitalCompletedPain | Benign Prostatic Hyperplasia | Prostate Cancer | Prostate Adenocarcinoma | Anxiety and Fear | Malignancy | Prostate DiseaseUnited States
-
Washington University School of MedicineFoundation for Anesthesia Education and ResearchCompletedCardiovascular AbnormalitiesUnited States
-
National Institute of Diabetes and Digestive and...CompletedAvitaminosis | Delirium, Dementia, Amnestic, Cognitive DisordersUnited States
-
University of ChicagoNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Opioid-Related DisordersUnited States
-
Baxter Healthcare CorporationCompleted